RT Book, Section
A1 Navada, Shyamala C.
A1 Silverman, Lewis R.
A2 Murray, Michael F.
A2 Babyatsky, Mark W.
A2 Giovanni, Monica A.
A2 Alkuraya, Fowzan S.
A2 Stewart, Douglas R.
SR Print(0)
ID 1102699983
T1 The Myelodysplastic Syndrome
T2 Clinical Genomics: Practical Applications in Adult Patient Care
YR 2014
FD 2014
PB McGraw-Hill Education
PP New York, NY
SN 9780071622448
LK accessbiomedicalscience.mhmedical.com/content.aspx?aid=1102699983
RD 2024/04/19
AB Disease  summary:The  myelodysplastic  syndrome  (MDS),  a  primary  bone  marrow  failure  state,  represents  a  heterogeneous  hematopoietic  stem  cell  disorder,  which  results  in  abnormal  cellular  maturation  and  peripheral  blood  cytopenias.  Greater  than  50%  of  patients  with  MDS  have  clonal  cytogenetic  abnormalities,  which  help  to  stratify  the  disease  into  poor,  intermediate,  and  good  prognostic  groups.  The  identification  of  recurrent  mutations  in  MDS  has  led  to  insights  into  the  pathophysiology  of  the  disease.MDS  is  primarily  a  disease  of  older  individuals  with  a  median  age  of  diagnosis  over  70  years.  It  is  more  common  in  males  than  females.Although  the  clinical  presentation  is  nonspecific,  symptoms  are  primarily  related  to  the  cytopenias.  The  most  common  cytopenia  is  anemia;  therefore,  patients  often  present  with  fatigue,  weakness,  dyspnea  on  exertion,  and  angina  pectoris.MDS  is  characterized  by  progressive  bone  marrow  failure,  and  the  most  common  causes  of  death  in  higher-risk  patients  are  infection  and  bleeding.Approximately  35%  to  40%  of  patients  with  MDS  progress  to  acute  myeloid  leukemia  (AML),  which  confers  a  poor  prognosis.